OncLive TV

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses trials investigating combinations of immunotherapy regimens in lung cancer.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Thomas F. Gajewski, MD, PhD, professor of medicine at The University of Chicago Medicine, discusses what targets are currently being explored in patients with melanoma.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

Ann Marie Beddoe, MD, assistant professor, Obstetrics, Gynecology and Reproductive Science, Gynecologic Oncology, Mount Sinai Hospital, discusses ongoing clinical trials for patients with cervical cancer.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the results of cohort G from the KEYNOTE-021 trial, which explored pembrolizumab (Keytruda) combined with pemetrexed/carboplatin as a frontline treatment for patients with nonsquamous non–small cell lung cancer (NSCLC).

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myeloma.

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the downfalls of chemotherapy in chronic lymphocytic leukemia (CLL).

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Thomas Hope, MD, assistant professor, UCSF Helen Diller Family Comprehensive Cancer Center, discusses imaging for patients with neuroendocrine tumors (NETs).